HPS2-THRIVE Trial Legacy Study
Research type
Research Study
Full title
HPS2-THRIVE trial legacy study: long-term follow-up of participants using electronic health records
IRAS ID
268340
Contact name
Jane Armitage
Contact email
Sponsor organisation
University of Oxford
ISRCTN Number
ISRCTN39960384
Duration of Study in the UK
19 years, 11 months, 30 days
Research summary
Dementia is a leading cause of death in the UK and affects many people. Dementia is a condition that develops over a long period before symptoms lead to diagnosis. Cardiovascular risk factors, such as LDL-cholesterol (an essential component of blood, which at increased levels can build up on the walls of arteries increasing the risk of heart disease), are associated with the risks of developing dementia. It is as yet unknown whether increased levels of LDL-cholesterol in older people are associated with increased risk of dementia, say 15-20 years later or longer.
Existing long-term follow-up studies, such as the large scale cardiovascular trial called HPS2-THRIVE, enables us to look at long-term outcome data in the older population now. We plan to look at the study records, health data (routinely collected health data is held in national central registries i.e. by NHS Digital) and existing stored blood and urine samples of HPS2-THRIVE participants to study the effect of LDL-cholesterol lowering on reducing the risk of developing dementia and other diseases such as the long-term risk of death, other important diseases (e.g. heart attacks, strokes and kidney disease) and healthcare use in the UK.
The primary aim of the study is to ask whether the different levels of LDL-cholesterol among participants in the HPS2-THRIVE study affect their long-term (up to 40 years) risk of dementia, death or other major diseases (e.g. heart attacks, strokes and kidney disease).
REC name
West of Scotland REC 3
REC reference
19/WS/0116
Date of REC Opinion
30 Aug 2019
REC opinion
Favourable Opinion